Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
To compare the safety and clinical efficacy (death, overall hospitalization, hospitalization
for influenza or pneumonia) of ID QIV delivered via an intradermal device with imiquimod
cream pretreatment with conventional intramuscular (IM) standard dose QIV and IM high-dose
TIV